HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells.

Abstract
Betulinic acid is a triterpene with selective cytotoxicity against melanoma, neuroectodermal and malignant brain tumor cell lines. In this study the betulinic acid activity was evaluated, in comparison with doxorubicin, on different human neoplastic and non-neoplastic cell lines and on proliferating normal lymphocytes. Growth inhibition was evident in all the neoplastic cell lines independently on p53 status and histotype. Antiproliferative activity of betulinic acid was related to a cytotoxic effect on two p53 wild-type and on one p53 mutant cell lines and to a cytostatic effect on one p53 mutant melanoma clone. At the same concentrations, normal cells were unaffected indicating a selective effect of this agent. A cytotoxic activity of doxorubicin was evident on all the tested systems. In vivo experiments, performed on one of these cell lines, confirmed the antineoplastic activity of this drug. These data support further preclinical studies of betulinic acid not confined to melanoma and neuroectodermal tumors independently of p53 status.
AuthorsValentina Zuco, Rosanna Supino, Sabina C Righetti, Loredana Cleris, Edoardo Marchesi, Carlo Gambacorti-Passerini, Franca Formelli
JournalCancer letters (Cancer Lett) Vol. 175 Issue 1 Pg. 17-25 (Jan 10 2002) ISSN: 0304-3835 [Print] Ireland
PMID11734332 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Tumor Suppressor Protein p53
  • betulonic acid
  • Oleanolic Acid
Topics
  • Antineoplastic Agents (toxicity)
  • Apoptosis (drug effects)
  • Cell Cycle (drug effects)
  • Cell Division (drug effects)
  • Cell Line
  • Cell Survival (drug effects)
  • Dose-Response Relationship, Drug
  • Exons
  • Genes, p53
  • Humans
  • Kinetics
  • Oleanolic Acid (analogs & derivatives, toxicity)
  • Reference Values
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p53 (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: